Adaptyv Bio offers an automated cloud lab platform that conducts protein assays and delivers clean, labeled data for AI-driven protein design within three weeks. The service integrates ordering, experiment management, and data analysis through a comprehensive API, enabling seamless incorporation into existing workflows. Transparent per‑protein pricing and real‑time progress updates help teams accelerate lab‑in‑the‑loop protein engineering cycles.

Aperture Therapeutics develops oligonucleotide therapeutics by identifying naturally occurring gene variants that confer protection against neurodegenerative diseases. The platform uses machine learning to analyze genomic and clinical datasets to prioritize protective gene variants for therapeutic mimicry. This approach targets genetically validated pathways to address shared drivers in ALS and FTD, expanding patient applicability beyond rare mutations.

Deciduous Therapeutics develops immune modulatory therapies that activate the body's natural immune mechanisms to eliminate senescent cells, which contribute to age-related diseases. By targeting these dysfunctional cells, the company aims to improve health span and mitigate the effects of inflammation and tissue remodeling associated with aging.

Herasight provides an embryo‑screening platform that uses ultra‑low‑pass whole‑genome sequencing combined with imputed genotype data to deliver both monogenic carrier detection and ancestry‑aware polygenic risk scores for complex diseases. The system integrates parental medical history, calibrates scores across diverse ancestries, and presents results through a secure web dashboard with optional genetic‑counselor support for IVF patients and fertility clinics.

ImmuneBridge is developing allogeneic cell therapies using proprietary expansion technology to amplify cord blood-derived immune stem cells while preserving their immune multipotency. This approach aims to provide a consistent and abundant cellular source for immunotherapies, making effective cancer treatments more accessible to patients.

Lucis offers preventive health screenings by analyzing key biomarkers through a network of partner laboratories. The platform provides personalized insights and actionable recommendations for lifestyle and nutrition, empowering individuals to proactively manage their well-being.

Oisin Biotechnologies develops genetic therapies utilizing Fusogenix™ Proteo-Lipid Vehicle technology to deliver DNA and RNA payloads for the treatment of age-related diseases. Their pipeline includes programs targeting frailty by promoting muscle growth, selectively eliminating fat cells, and removing senescent cells.

Renewal Bio develops synthetic embryo models derived from pluripotent stem cells to study early human development. The company utilizes advanced stem cell biology to generate in vitro models that mimic post-implantation stages of embryogenesis. This platform aims to advance understanding of human biology and developmental processes.

Revel Pharmaceuticals develops therapies that target the excess accumulation of toxic proteins and metabolites, aiming to repair age-related damage and complications from chronic diseases such as osteoarthritis and diabetes. By addressing the root causes of aging and chronic illness, their solutions offer a pathway to reverse disease progression and improve patient outcomes.

Syntax Bio provides a discovery platform that uses its proprietary Cellgorithm technology to directly control and accelerate stem cell differentiation, mimicking human developmental cues to produce a wide variety of functional cell types. The platform shortens development timelines, lowers costs, and offers scalable, reproducible workflows that act as a force multiplier for large biopharma and cell therapy programs, enabling faster preclinical and clinical translation of therapies such as pancreatic beta cells for type 1 diabetes.

Teal provides a modular API and front-end code snippets that enable SMB software companies to integrate accounting products directly into their platforms, creating a centralized financial operating system for their customers. This solution allows businesses to access critical financial insights and automate accounting tasks, enhancing customer engagement and retention.

Vincere Biosciences develops novel therapeutics targeting Parkinson's disease and age-related kidney disease, utilizing proprietary AI/ML tools to design and optimize drug candidates. Backed by over $2.7 million in grants from organizations like the NIH and the Michael J. Fox Foundation, the company aims to initiate human trials for its first molecule within 18 months.